Search research articles
Contact Us
Filters
Showing results (91-100 of 145) with videos related to
Page
of 15
Sort By:
The Pharmacogenomics Journal
|
July 19, 2017
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
T Magnes, T Melchardt, C Hufnagl, et al.
ESMO Open
|
February 6, 2026
Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial
T Fuereder, K Klinghammer, D Hahn, et al.
BMC Cancer
|
May 8, 2020
Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial
V Bjelic-Radisic, F Fitzal, M Knauer, et al.
The British Journal of Surgery
|
February 20, 2021
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial
F Fitzal, M Filipits, C Fesl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2002
The impact of hemoglobin levels on fatigue and quality of life in cancer patients
B Holzner, G Kemmler, R Greil, et al.
The Pharmacogenomics Journal
|
May 4, 2016
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer
S P Gampenrieder, C Hufnagl, S Brechelmacher, et al.
European Journal of Immunology
|
November 11, 1999
Synergistic action of protein kinase C theta and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells
A Villunger, N Ghaffari-Tabrizi, I Tinhofer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 16, 2013
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
S Kubicka, R Greil, T André, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
I Lang, M J Inbar, Z Kahán, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2018
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
A Matikas, T Foukakis, V Moebus, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 145) with videos related to
Sort By:
Page
of 15
The Pharmacogenomics Journal
|
July 19, 2017
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
T Magnes, T Melchardt, C Hufnagl, et al.
ESMO Open
|
February 6, 2026
Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial
T Fuereder, K Klinghammer, D Hahn, et al.
BMC Cancer
|
May 8, 2020
Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial
V Bjelic-Radisic, F Fitzal, M Knauer, et al.
The British Journal of Surgery
|
February 20, 2021
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial
F Fitzal, M Filipits, C Fesl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2002
The impact of hemoglobin levels on fatigue and quality of life in cancer patients
B Holzner, G Kemmler, R Greil, et al.
The Pharmacogenomics Journal
|
May 4, 2016
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer
S P Gampenrieder, C Hufnagl, S Brechelmacher, et al.
European Journal of Immunology
|
November 11, 1999
Synergistic action of protein kinase C theta and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells
A Villunger, N Ghaffari-Tabrizi, I Tinhofer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 16, 2013
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
S Kubicka, R Greil, T André, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
I Lang, M J Inbar, Z Kahán, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2018
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
A Matikas, T Foukakis, V Moebus, et al.
Page
of 15